Candidate selection underscores Confo’s ability to rapidly advance differentiated GPCR-targeting therapeutics and its focus ...
Re-treatment with ligelizumab is effective and generally well tolerated in patients with chronic spontaneous urticaria who ...
Funding to support Phase 1 clinical development of best-in-class PARG inhibitor candidate FORX-428FORX-428 is potential new treatment option for ...
UCSF's Dr Laura Huppert explores a phase 2 trial assessing ARX788's safety and efficacy for HER2-low breast cancer patients, ...
The Trump administration's funding cuts to PEPFAR and USAID disrupted global HIV treatment and prevention, threatening progress made over decades. Lenacapavir's FDA approval as a long-acting ...
Traws Pharma reports interim Phase 2 data showing ratutrelvir performed comparably to Paxlovid in mild-to-moderate COVID-19 ...
Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing ...
LINKER-MM4 trial shows linvoseltamab monotherapy achieves a 79% overall response rate in newly diagnosed MM patients, with 92 ...
The insulin storage system market offers key opportunities in enhancing storage infrastructure for compliance and reliability, integrating IoT for real-time monitoring, and utilizing portable ...
Eilean Therapeutics announced the advancement of ZE74-0282 into first-in-human clinical development. ZE74-0282 is a novel, highly selective inhibitor of the mutated Janus kinase 2 (JAK2) V617F variant ...
CorestemChemon (KOSDAQ: 166480) is entering a critical late-stage phase in the commercialization of its ALS stem cell therapy, Neuronata-R. The company attributes this momentum to advanced domestic ...
Background In 2024, the UK National Institute of Health and Care Excellence (NICE) recommended TriageHF alerts as an option ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback